Carlsmed financials
$14.09−0.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 |
|---|---|---|---|---|
| Revenue | $18.9M | $16.1M | $15.2M | $13.1M |
| Gross profit | $14.5M | $12.4M | $11.6M | $9.9M |
| Gross margin | 76.8% | 77.1% | 76.5% | 75.9% |
| Operating income | -$11.0M | -$9.3M | -$9.3M | -$9.0M |
| Net income | -$10.5M | -$8.7M | -$8.6M | -$8.5M |
| Net margin | −55.5% | −54.0% | −56.8% | −65.2% |
| Diluted EPS | $-0.39 | $-0.32 | $-0.32 | $-0.40 |
| EBITDA | -$10.9M | -$9.2M | -$9.2M | -$9.0M |
| Operating cash flow | -$7.4M | -$13.0M | -$5.3M | -$8.5M |
| Free cash flow | -$7.5M | -$13.1M | -$5.6M | -$8.8M |
| Diluted shares | 27.2M | 26.8M | 26.9M | 21.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $46.2M | $73.0M | $85.8M | $115.4M |
| Short-term investments | $43.0M | $24.0M | $24.0M | $0.00 |
| Total debt | $15.4M | $15.4M | $15.3M | $15.4M |
| Total assets | $118.2M | $118.8M | $130.1M | $134.9M |
| Total liabilities | $34.0M | $26.5M | $31.3M | $28.2M |
| Shareholders' equity | $84.2M | $92.2M | $98.9M | $106.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology